Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHRM.L Regulatory News (PHRM)

  • There is currently no data for PHRM

Issue of Equity

4 Nov 2011 07:30

RNS Number : 4915R
Phorm Inc
04 November 2011
 



4 November 2011

Phorm Inc

("Phorm" or the "Company")

Expansion of Equity Placing to £33.6m

Issuance of Call Notices for existing £16.075m Convertible Loan Notes

Phorm (AIM: PHRM and PHRX), the internet personalization technology company, is pleased to announce an expansion of the £30.0m equity placing with institutional and other investors announced on 21 October 2011 to a total of £33.6m (the "Placing").

The proceeds from the Placing will be used to redeem the convertible loan notes ("CLNs") issued on 21 March 2011 (together with the Placing, the "Transaction") and to provide sufficient working capital to get to positive operational cash flow and develop the opportunities previously described.

The Company announces that call notices to all holders of the £16,075,000 CLNs will be served today. The CLNs will be redeemed on 11 November 2011 using a combination of cash and shares. The total cash repayable is £17.6m, being the £16.1m principal together with £1.5m of coupon (accrued at a rate of 15% per annum since the issue date of the CLNs). In addition, the Company must provide investors with a minimum threshold return of 1.1 times the principal (a nominal total of £17.7m) (the "Redemption Premium") as the CLNs are being redeemed in the first year of issue. Phorm has opted to satisfy the balance of the Redemption Premium Return in Shares. The Redemption Premium Shares are to be issued at a price of 98.30p per Share, being the average of the lowest five daily closing prices over the 20 day trading period immediately prior to the redemption notice being given. The total number of Redemption Premium Shares to be issued will be 17,988,302.

The total number of Shares that will be issued pursuant to the Placing will be 39,023,306 at a Placing price per Share of 86.10p. Accordingly, the total number of Shares to be issued by the Company pursuant to the Transaction is 57,011,608.

Application has been made for the Transaction Shares to be admitted to trading on the AIM Market of the London Stock Exchange Plc ("AIM") and trading of the Placing Shares and Redemption Premium Shares is expected to commence at 8.00 am on 10th and 11th November 2011 respectively.

Following the Transaction, the total issued share capital of the Company will comprise 75,491,515 Shares with a nominal value of $0.001 each, with each Share conveying the right to one vote of which 74,654,564 are trading on AIM under the ticker PHRM, the Reg S line and 836,951 are trading on AIM under the ticker PHRX, the unrestricted line. Phorm holds 45,000 PHRM shares in treasury.

 The Company's net proceeds (before expenses) from the Transaction (being the proceeds of the Placing less the cash amounts repayable upon redemption of the CLNs) will be approximately £16.0m.

Related Party Transaction

Mark Schneider, a non-executive director of the Company, has transferred £0.5m of his original £1.6m commitment in the Placing to Global Family Partners Ltd., which remains on the same terms and conditions as the other investors and previously announced. As Mr Schneider is a director, this constitutes a related party transaction for the purposes of Rule 13 of the AIM Rules and the directors of Phorm, other than Mr Schneider, consider, having consulted with Canaccord Genuity Limited (the Company's nominated advisor), that the terms of these transactions are fair and reasonable insofar as the Company's shareholders are concerned.

Enquiries:

Phorm, Inc

Andy Croxson (analysts & investors) +44 20 7297 2326

Alex Laity (media) +44 20 7297 2710

 

Brokers

Canaccord Genuity Limited +44 20 7050 6500

(Nominated Adviser)

Andrew Chubb

 

Mirabaud Securities LLP +44 20 321 2508

(Joint Broker)

Peter Krens

 

Evolution Securities Limited +44 20 7071 4300

(Joint Broker)

Stuart Andrews

 

About Phorm:

Phorm is a global personalisation technology company that makes content and advertising more relevant to the consumer. Phorm's innovative platform preserves user privacy and delivers a more interesting online experience.

Phorm's partners include leading Internet Service Providers (ISPs), Publishers, Ad Networks and Advertisers.

Phorm is a Delaware, US incorporated company, with offices in Bucharest, Seoul, Sao Paolo and London.

The Company was admitted to the AIM market of the London Stock Exchange in 2004 and has over 140 employees and contractors.

For more information, please visit: www.phorm.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOELFFLFLSLVIIL
Date   Source Headline
26th Mar 20145:00 pmRNSIntention to raise £10 million
10th Mar 20147:01 amRNSMemorandum of Understanding with China Telecom
27th Jan 20147:00 amRNSCommercial Launch in China
20th Jan 20147:00 amRNSChange of Adviser
17th Jan 20147:00 amRNSAIM Rule 17 Disclosure Schedule Two (g) Update
6th Jan 20147:00 amRNSExercise of Employee Warrants for Shares
19th Nov 20137:00 amRNSEquity Placing to raise £10 million
19th Nov 20137:00 amRNSOperational Update for Phorm China
13th Nov 20137:12 amRNSStmnt re Share Price Movement
24th Oct 201311:16 amRNSOperations Update
3rd Oct 20137:00 amRNSOperational Launch in China
30th Sep 20137:00 amRNSInterim Results
27th Sep 20137:00 amRNSOperations Update
28th Aug 201312:43 pmRNSAGM Statement
7th Aug 201310:52 amRNSStmnt re Share Price Movement
6th Aug 20137:00 amRNSAGM Statement
26th Jul 20137:00 amRNSTR1: Notification of major interest in shares
26th Jul 20137:00 amRNSTR1: Notification of major interest in shares
17th Jul 20139:20 amRNSIssue of Equity
28th Jun 20137:20 amRNSAnnual Report and Financial Statements
28th Jun 20137:20 amRNSTurkish Operations Update
29th May 20137:00 amRNSFinancing Update
8th May 20138:34 amRNSHolding(s) in Company
23rd Apr 201310:18 amRNSPlacing to raise £7.15 million
21st Mar 20133:20 pmRNSStatement re Share Price Movement
20th Mar 20137:00 amRNSFinancing Update
24th Jan 20137:00 amRNSChinese and Turkish Operations Update
4th Jan 20137:00 amRNSIssue of Shares
18th Dec 20127:00 amRNSIssue of Shares
17th Dec 20127:00 amRNSTurkish Operational Update
13th Dec 20127:00 amRNSTR1: Notification of major interest in shares
21st Nov 201212:33 pmRNSResult of EGM & Admission to trading
6th Nov 201211:50 amRNS£6m Placing, Contract Signature & Turkey Update
16th Oct 20127:00 amRNSCommercial Progress Update
28th Sep 20127:00 amRNSInterim Results
20th Sep 20127:00 amRNSUpdate on Turkey and Phorm China Equity Fundraise
11th Sep 20127:00 amRNSAdmission to Trading
10th Sep 20123:33 pmRNSSch 1 Update - Phorm Corporation Limited
7th Sep 20122:58 pmRNSResults of EGM - Correction
7th Sep 201212:29 pmRNSResults of EGM
5th Sep 20124:15 pmRNSNotification of Major Interests in Shares
31st Aug 20123:49 pmRNSUpdated Appendix to Schedule 1
13th Aug 20129:06 amRNSSchedule 1 - Phorm Corporation Limited
13th Aug 20127:00 amRNSPhorm Re-Domicile of Holding Company from Delaware
2nd Aug 20127:00 amRNSPlacing
9th Jul 20127:00 amRNSCommencement of Commercial Activities with TTNET
3rd Jul 201210:14 amRNSTransfer of Shares
29th Jun 20127:00 amRNSAnnual Financial Report
19th Jun 20126:01 pmRNSCorrection: AGM Result
19th Jun 201211:29 amRNSAGM Result

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.